ArticleTherapeutic advances in neurological disorders2025
Long-term efficacy of deep brain stimulation in Parkinson's disease: over 10-year follow-up and insights into the "DBS honeymoon".
Article in Therapeutic advances in neurological disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deep brain stimulation battery longevity: a cohort study comparing impact of anaesthesia modality and anatomic target.BMJ neurology open · 2026Article
- Deep Brain Stimulation Withdrawal Syndrome in Parkinson's Disease: Clinical Features and Outcomes of Two New Cases.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder globally. Deep brain stimulation (DBS) has become a critical therapeutic option for advanced PD. The efficacy of DBS has been well established for up to 1 or 2 years; however, long-term outcome data for Chinese cohorts are limited, and the duration of the "DBS honeymoon" remains underexplored. Objective: This study aimed to evaluate the long-term efficacy (⩾10 years) of subthalamic nucleus (STN)-DBS in patients with PD in Southern China, and to investigate the duration of "DBS honeymoon." Design: Retrospective study. Methods: Thirty-one patients who underwent bilateral STN-DBS between 2010 and 2011 were assessed. Motor symptoms were evaluated using the Unified Parkinson's Disease Rating Scale-Part III (UPDRS-III) in the off- and on-medication states with stimulation. Nonmotor symptoms and the quality of life (QOL) were measured using validated scales. The levodopa equivalent daily dose (LEDD), stimulation parameters, and adverse events were recorded. Genetic testing was performed for seven patients. Results: Thirteen patients completed the follow-up at 1, 3, and ⩾10 years. The UPDRS-III (off-state) scores improved by 53.02%, 44.79%, and 22.56% at 1, 3, and ⩾10 years, respectively. Tremor and rigidity showed sustained improvement; sleep remained stable postoperatively. In contrast, emotion, cognition, and QOL improved at 3 years; however, they returned to baseline or declined beyond 10 years. The LEDD reductions were 36.29%, 40.40%, and 29.10% at 1, 3, and ⩾10 years, respectively. Stimulation frequency decreased from 141.70 ± 15.72 Hz at 1 year to 110.00 ± 18.22 Hz ⩾10 years. Additionally, genetic testing identified three mutation carriers and rare complications such as DBS withdrawal syndrome appeared beyond 10 years. Conclusion: STN-DBS provided sustained motor improvement, with tremor and rigidity showing the most significant benefits after 10 years. The initial 3 years likely represented a "DBS honeymoon," with peak improvements in motor and nonmotor symptoms. Genotype may influence the efficacy of DBS, and monitoring rare complications is essential. These findings should be interpreted with caution, given the small sample size and the retrospective design of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.